You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

TETRACHEL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tetrachel, and when can generic versions of Tetrachel launch?

Tetrachel is a drug marketed by Angus and is included in one NDA.

The generic ingredient in TETRACHEL is tetracycline hydrochloride. There are ninety-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the tetracycline hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tetrachel

A generic version of TETRACHEL was approved as tetracycline hydrochloride by WATSON LABS on December 31st, 1969.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TETRACHEL?
  • What are the global sales for TETRACHEL?
  • What is Average Wholesale Price for TETRACHEL?
Summary for TETRACHEL
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 64
DailyMed Link:TETRACHEL at DailyMed
Drug patent expirations by year for TETRACHEL

US Patents and Regulatory Information for TETRACHEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Angus TETRACHEL tetracycline hydrochloride CAPSULE;ORAL 060343-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Angus TETRACHEL tetracycline hydrochloride CAPSULE;ORAL 060343-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

TETRACHEL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Generic Drugs: A Case Study on Tetracyclines

Introduction

Generic drugs, including tetracyclines like doxycycline and minocycline, play a crucial role in the pharmaceutical market due to their affordability and widespread use. Understanding the market dynamics and financial trajectory of these drugs is essential for both industry stakeholders and policymakers.

Market Competition and Price Dynamics

Impact of Number of Competitors

The generic drug market, including tetracyclines, is heavily influenced by the number of competitors. Studies have shown that as more firms enter the market, prices tend to decrease. For instance, generic drug prices fall with the number of competitors but remain above long-run marginal costs until there are 8 or more competitors[1].

Example of Doxycycline Hyclate

A notable example is the significant price increase of doxycycline hyclate between 2011 and 2013. Despite the market being highly concentrated, the mean cost of doxycycline hyclate prescriptions skyrocketed from $7.16 to $139.89. This increase cannot be fully explained by competitive market forces, suggesting noncompetitive market forces may be at play[3].

Entry Process and Regulatory Environment

FDA Approval and Entry Timing

The entry process for generic drugs is complex and influenced by FDA approval. The timing of entry is not fully under the control of the entrant, as FDA approval dates are uncertain and multiple firms may be approved simultaneously. This uncertainty affects the share of aggregate generic profits for each entrant[1].

Policy Changes and Their Impact

Changes in FDA policies can significantly impact the market. For example, increased scrutiny of generic drug applications in the late 1980s raised the cost of obtaining FDA approval, which can lead to higher generic prices. Simultaneous approval of multiple generic entrants can lower prices initially but may reduce expected rents, leading to fewer firms applying for FDA approval in the long run[1].

Financial Trajectory

Revenue and Profit Dynamics

The financial trajectory of generic drugs is characterized by an initial period of high profits followed by a decline as more competitors enter the market. Generic industry profits increase as revenues grow but begin falling after five to eight months as more entrants compete away price-cost margins[1].

Cost Increases and Prescribing Practices

The dramatic increase in the cost of doxycycline hyclate did not significantly alter clinicians' prescribing behavior, indicating a need for interventions to promote the use of less costly substitutes. This highlights the financial strain on healthcare systems and patients due to unpredictable price increases[3].

Market Concentration and Noncompetitive Forces

Herfindahl-Hirschman Index

The Herfindahl-Hirschman index (HHI) is often used to measure market concentration. In the case of doxycycline hyclate, the market remained highly concentrated throughout the study period, yet the price increase was not significantly associated with market concentration. This suggests that noncompetitive market forces, such as supply chain disruptions or monopolistic practices, may be driving these price increases[3].

Impact on Access to Medications

Access and Affordability

Recent generic price increases, such as those seen with tetracyclines, threaten access to these essential medications. The significant price hikes make these drugs less affordable for patients, particularly those without adequate insurance coverage. This can lead to reduced adherence to treatment and poorer health outcomes[3].

Policy Implications

Regulatory Oversight

Policymakers must balance the need for stringent regulatory oversight with the necessity of fostering a competitive market. Increased FDA scrutiny, while ensuring drug safety, can raise barriers to entry and contribute to higher prices. Policies that encourage simultaneous approval of multiple generic entrants can help mitigate these effects[1].

Cost Recovery Mechanisms

Healthcare systems, especially in developing countries, face challenges in maintaining affordable access to drugs. Implementing cost recovery mechanisms, such as user fees and revolving funds, can help sustain healthcare services but must be carefully designed to avoid exacerbating affordability issues[2].

Conclusion

The market dynamics and financial trajectory of generic drugs like tetracyclines are complex and influenced by a variety of factors, including competition, regulatory policies, and noncompetitive market forces. Understanding these dynamics is crucial for ensuring affordable access to essential medications.

Key Takeaways

  • Generic drug prices decrease with the number of competitors but remain above long-run marginal costs until there are 8 or more competitors.
  • FDA approval processes and policy changes significantly impact the market dynamics and financial trajectory of generic drugs.
  • Noncompetitive market forces can drive significant price increases, even in highly concentrated markets.
  • Access to medications is threatened by unpredictable price increases, highlighting the need for effective regulatory oversight and cost recovery mechanisms.

FAQs

What is the impact of the number of competitors on generic drug prices?

Generic drug prices fall with the number of competitors but remain above long-run marginal costs until there are 8 or more competitors[1].

How do FDA policy changes affect the generic drug market?

FDA policy changes, such as increased scrutiny of applications or simultaneous approval of multiple generic entrants, can influence the number of firms entering the market and the resulting prices[1].

Why did the price of doxycycline hyclate increase significantly between 2011 and 2013?

The significant price increase of doxycycline hyclate between 2011 and 2013 cannot be fully explained by competitive market forces, suggesting noncompetitive market forces may be responsible[3].

How do cost recovery mechanisms impact access to generic drugs?

Cost recovery mechanisms, such as user fees and revolving funds, can help sustain healthcare services but must be carefully designed to avoid exacerbating affordability issues for patients[2].

What is the role of regulatory oversight in the generic drug market?

Regulatory oversight is crucial for ensuring drug safety, but it must be balanced with the need to foster a competitive market to keep prices affordable[1].

Sources

  1. Federal Trade Commission. Generic Drug Industry Dynamics. February 2002.
  2. World Bank. National Health Project - The Gambia - Credit 1760 - P000812. October 2, 2019.
  3. PubMed. Influence of Market Competition on Tetracycline Pricing and Impact on Prescribing Practices. Published by Elsevier Inc., 2017.
  4. United Nations Office on Drugs and Crime. DRUG MARKET TRENDS. June 13, 2022.
  5. U.S. Food and Drug Administration. Toxicological Principles for the Safety Assessment of Food Ingredients. July 5, 2007.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.